Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 299

1.

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.

Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.

AIDS. 2000 Sep 29;14(14):2137-44.

PMID:
11061655
[PubMed - indexed for MEDLINE]
2.

Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.

Anderson PL, Kakuda TN, Kawle S, Fletcher CV.

AIDS. 2003 Oct 17;17(15):2159-68.

PMID:
14523272
[PubMed - indexed for MEDLINE]
3.

Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.

Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.

AIDS. 2000 Apr 14;14(6):671-81. Erratum in: AIDS 2000 Jun 16;14(9):1295.

PMID:
10807190
[PubMed - indexed for MEDLINE]
4.

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC.

AIDS. 2002 Mar 8;16(4):551-60.

PMID:
11872998
[PubMed - indexed for MEDLINE]
5.

Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.

Goodgame JC, Pottage JC Jr, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L.

Antivir Ther. 2000 Sep;5(3):215-25.

PMID:
11075942
[PubMed - indexed for MEDLINE]
6.

Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.

Hurwitz SJ, Schinazi RF.

Antiviral Res. 2002 Nov;56(2):115-27.

PMID:
12367718
[PubMed - indexed for MEDLINE]
7.

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.

Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):116-23.

PMID:
11404532
[PubMed - indexed for MEDLINE]
8.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
[PubMed - indexed for MEDLINE]
9.

Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.

Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV.

AIDS. 2007 Sep 12;21(14):1849-54.

PMID:
17721092
[PubMed - indexed for MEDLINE]
10.

Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.

Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM.

AIDS. 1997 Feb;11(2):169-75.

PMID:
9030363
[PubMed - indexed for MEDLINE]
11.

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.

Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP.

Antivir Ther. 2007;12(6):981-6.

PMID:
17926654
[PubMed - indexed for MEDLINE]
12.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
[PubMed - indexed for MEDLINE]
13.

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, Kapoor A, Lloyd J, Barry MG, Back D.

AIDS. 1999 Nov 12;13(16):2239-50.

PMID:
10563709
[PubMed - indexed for MEDLINE]
14.

Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.

Rodriguez JF, Rodriguez JL, Santana J, García H, Rosario O.

Antimicrob Agents Chemother. 2000 Nov;44(11):3097-100.

PMID:
11036029
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.

Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD.

JAMA. 1998 Jul 1;280(1):35-41.

PMID:
9660361
[PubMed - indexed for MEDLINE]
16.

Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.

Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM.

Antivir Ther. 2001 Mar;6(1):55-62.

PMID:
11417762
[PubMed - indexed for MEDLINE]
17.

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.

Hawkins T, Veikley W, St Claire RL 3rd, Guyer B, Clark N, Kearney BP.

J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):406-11.

PMID:
16010161
[PubMed - indexed for MEDLINE]
18.

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM; ACTG 303 Study Team.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1337-44.

PMID:
11018853
[PubMed - indexed for MEDLINE]
19.

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC Jr, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY; Protocol 054/069 Study Teams.

AIDS. 2000 Sep 8;14(13):1973-8.

PMID:
10997402
[PubMed - indexed for MEDLINE]
20.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk